BMY

#128
Bristol-Myers Squibb Company Common Stock
57.1 8 USD
+0.62%
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
56.82
57.26
Intervallo Annuale
42.52
62.89
Variazione giornaliera
+0.62%
Variazione Mensile
-0.92%
Variazione di 6 mesi
+15.94%
Variazione Annuale
+19.50%
Chiusura Precedente
56.8 3
Open
56.9 0
Minimo
56.8 2
High
57.2 6
Volume
7 641
Apri il grafico completo Full chart

Financials

Panoramica Estratto Conto Statistiche Dividendi
Trimestrale Annuale
Conto economico Bilancio Liquidità
Valore Q4, 24Q1, 25Q2, 25Q3, 25Q4, 25Q1, 26 TTM

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban for people with atrial fibrillation; nivolumab, used to treat certain types of cancer; lenalidomide, used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes; abatacept, used to treat autoimmune diseases such as rheumatoid arthritis; pomalidomide, an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma; ipilimumab, to treat cancer; and luspatercept for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2024, 71% of the company's revenues came from the United States. The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000.

Notizie